Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | March 25, 2014

Key Technologies Highlighted as Late-Breakers at ACC.14

By Dave Fornell, DAIC editor

Data from several cutting-edge device clinical trials will be presented as late-breakers at the American College of Cardiology 63rd Annual Scientific Session & Expo (ACC.14), March 28-31.  

One of the most anticipated therapies on the interventional front is the use of renal denervation to treat drug resistant hypertension. However, its future was called into question recently when Medtronic announced it failed to meet the primary endpoints in its SYMPLICITY HTN-3 U.S. pivotal trial. The results of that trial will be presented at ACC on Saturday. Experts say this is not the end of the story, and additional data might be revealed in another late-breaker with data from the Global SYMPLICITY Registry. 

Also on the interventional front, the NEXT trial is among the first to compare a biodegradable polymer drug-eluting stent (DES) with a durable polymer DES. 

In electrophysiology, the use of cardiac resynchronization therapy (CRT) devices was expanded a few years ago to patients with mild heart failure. One of the late breakers will discuss long-term survival in this CRT population.

In structural heart, three key presentations are featured. The CHOICE Trial will compare self-expanding (Medtronic’s Corevalve) to balloon expandable (Edwards’ Sapien) TAVR devices. Another compares the Corevalve with surgical outcomes in patients deemed high risk for surgery. The final session will share one-year outcomes from the STS/ACC Transcatheter Valve Therapy Registry.

Complete list of ACC late-breaking trials

For information on ACC.14, the official site is accscientificsession.cardiosource.org 

Related Content

An example of renal denervation therapy being delivered. A catheter is inserted into the renal artery to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys.

An example of renal denervation therapy being delivered. A catheter is inserted into the renal artery to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys.

Feature | Renal Denervation | May 30, 2018
May 30, 2018 — Despite the best efforts of clinicians to manage hypertension, it continues to increase and is now rea
Paradise Renal Denervation System Shows Significant Blood Pressure Reduction in Hypertensive Patients. PCR, #euroPCR 2018
News | Renal Denervation | May 30, 2018
ReCor Medical announced that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a...
Renal Denervation Shows Significant Drop in Hypertension
News | Renal Denervation | May 23, 2018
At the 2018 EuroPCR Annual Meeting in Paris, Medtronic announced first-ever-data from the SPYRAL HTN-ON MED Study....
Medtronic Announces Renal Denervation Pivotal Trial for Hypertension Treatment
News | Renal Denervation | April 16, 2018
Medtronic plc announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (...
SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation
News | Renal Denervation | August 31, 2017
Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial following positive first...
News | Renal Denervation | October 11, 2016
Awards from the National Institutes of Health’s Common Fund are supporting research on the peripheral nervous system,...
Technavio report, renal denervation devices, 2015
News | Renal Denervation | August 23, 2016
August 23, 2016 — Technavio analysts forecast the global...
renal denervation, resistant hypertension, rat study, American Journal of Physiology
News | Renal Denervation | February 17, 2016
February 17, 2016 — Up to 10 percent of people with high blood pressure have...
Videos | Renal Denervation | November 03, 2015
Robert Schwartz, M.D., medical director at the Minnesota Heart Institute, explains new applications for denervation t
Overlay Init